Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b | WAPE

Back All news

Newsfiscal.ai

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b

Oct 19, 2026, 09:03 ET · Published

View source

Article summary

Zentalis Pharmaceuticals reported interim overall survival data for its lead product candidate, azenosertib, from the DENALI Part 1b study in patients with Cyclin E1-positive platinum-resistant ovarian cancer.

An excerpt from the original article.

Related companies

Zentalis Pharmaceuticals, Inc. Common StockZNTLView stock

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b

Article summary

Related companies

Analyzed by WAPE AI.

Comments —